Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
Clinical trial NCT06093503 · WITHDRAWN
Trial details
- NCT number
- NCT06093503
- Sponsor
- AbbVie
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-31
- Primary completion
- 2028-04-11
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.